Powder: -20℃ for 3 years. In solvent: -80℃ for 1 year.
Synonyms
PF02341066
Description
Crizotinib, an orally bioavailable agent, belongs to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.